NIH grant award of $2.3M will support clinical development of the company’s orphan-designated first-in-class CPT1 inhibitor for the treatment of glioblastoma.

The notable strengths of this project include the high significance of developing new targeted approaches to tackle deadly glioblastoma.”

— NIH Study Section Summary Statement

DENVER, CO, UNITED STATES, September 21, 2026 /EINPresswire.com/ — Numiera Therapeutics Inc. (“Numiera”), a pharmaceutical company dedicated to developing groundbreaking treatments for aggressive solid tumors, today announced a NCI Direct-To-Phase II SBIR Grant Award of $2.3M. This funding will support an early-phase clinical trial to evaluate the first-in-class CPT1 inhibitor etomoxir in the treatment of glioblastoma (GBM).

This effort will build on previous Phase I data establishing preliminary dose safety data with this drug. With the support of this SBIR grant award, the Numiera Therapeutics team will run a dose-escalation and window-of-opportunity study in patients with recurrent glioblastoma. This study has three major goals: to identify the maximum tolerated dose in this neuro oncology patient population, to study the pharmacology of the drug in resected brain tumor tissue, and to seek an initial efficacy signal. Successful results from the study are expected to pave the way for later-phase clinical trials.

The NIH brought together experts in medical oncology across the United States to review the team’s proposed clinical trial. That group released the following summary statement: “The notable strengths of this project include the high significance of developing new targeted approaches to tackle deadly glioblastoma, the innovation of targeting fatty acid oxidation in this cancer, the outstanding team with strong record of accomplishments in drug development and glioblastoma, and the clinical trial outlined in excellence with appropriate statistical design.”

Dr. Izi Stoll, Co-Founder and CEO of Numiera Therapeutics, stated: “The recent FDA approvals and billion-dollar transactions involving vorasidenib and dordaviprone in neuro oncology indications have shown that mitochondrial-targeting small-molecule drugs are a complete game-changer in the field. With an even broader mitochondrial target, orphan designation for all malignant gliomas, independent validation in five different preclinical models from five different laboratories, and promising Phase I safety data for our lead drug candidate, we believe our approach will have a significant impact in this space.”

About The Company:
Numiera Therapeutics is dedicated to pioneering the development of new oncology drugs by targeting cancer cell metabolism. With an orphan-designated lead asset and a growing pipeline, its mission is to transform cancer patient care, by developing safer and more effective therapies especially designed to treat chemotherapy-resistant solid tumors. The Direct-To-Phase II SBIR Grant Award Number, issued to Numiera Therapeutics, Inc. by the National Cancer Institute, is 1R44CA310352-01.

Forward Looking Statements
To the extent statements contained in this news release are not descriptions of historical facts regarding Numiera Therapeutics Inc., they should be considered “forward-looking statements,” as described in the private securities litigation reform act of 1995. Forward-looking statements can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” “plan,” “expect,” “explore,” “potential” or similar expressions that convey uncertainty of future events or outcomes. Any statement describing Numiera’s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements which are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for interim or final results and data related to Numiera’s clinical and non-clinical trials, or third-party trials evaluating Numiera’s candidate products, the timing and plans with respect to enrollment of patients in Numiera’s clinical trials, the potential benefits of Numiera’s drug candidates, and Numiera’s strategy and plans with respect to its business and research programs. Such statements are based on Numiera’s expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks associated with clinical and preclinical trials and product development, the risk that interim data may not be reflective of final data, risks related to regulatory approvals, and risks related to the impact of global economic conditions. The company undertakes no obligation to publicly update any forward-looking statement, except as required under applicable law.

Anjali Hansen
Numiera Therapeutics
hansen@numiera.com
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Media gallery

About The Author
Written By: EIN Presswire